Listed

Edwards Lifesciences Corp: Form 10-K for the period ended Dec 31, 2021

Filed with the SEC on Feb 14, 2022 and accepted by EDGAR at Feb 14, 2022, 16:15 ET.

Share

Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2021-12-31. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Revenue12 months2021-01-01 to 2021-12-31$5.23bnus-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
Cost of revenue12 months2021-01-01 to 2021-12-31$1.25bnus-gaap:CostOfGoodsAndServicesSold
Gross profit12 months2021-01-01 to 2021-12-31$3.98bnus-gaap:GrossProfit
Research and development12 months2021-01-01 to 2021-12-31$903.1mus-gaap:ResearchAndDevelopmentExpense
Selling, general and administrative12 months2021-01-01 to 2021-12-31$1.49bnus-gaap:SellingGeneralAndAdministrativeExpense
Operating income12 months2021-01-01 to 2021-12-31$1.69bnus-gaap:OperatingIncomeLoss
Interest expense12 months2021-01-01 to 2021-12-31$18.4mus-gaap:InterestExpense
Income tax12 months2021-01-01 to 2021-12-31$198.9mus-gaap:IncomeTaxExpenseBenefit
Diluted EPS12 months2021-01-01 to 2021-12-31$2.38us-gaap:EarningsPerShareDiluted
Basic EPS12 months2021-01-01 to 2021-12-31$2.41us-gaap:EarningsPerShareBasic
Diluted shares (weighted)12 months2021-01-01 to 2021-12-31631,200,000 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Operating cash flow12 months2021-01-01 to 2021-12-31$1.73bnus-gaap:NetCashProvidedByUsedInOperatingActivities
Capital expenditure12 months2021-01-01 to 2021-12-31$325.8mus-gaap:PaymentsToAcquirePropertyPlantAndEquipment
Share repurchases12 months2021-01-01 to 2021-12-31$512.8mus-gaap:PaymentsForRepurchaseOfCommonStock
Cash and equivalentsAt period end2021-12-31$862.8mus-gaap:CashAndCashEquivalentsAtCarryingValue
Current assetsAt period end2021-12-31$3.18bnus-gaap:AssetsCurrent
Total assetsAt period end2021-12-31$8.50bnus-gaap:Assets
Current liabilitiesAt period end2021-12-31$1.03bnus-gaap:LiabilitiesCurrent
Total liabilitiesAt period end2021-12-31$2.67bnus-gaap:Liabilities
Long-term debtAt period end2021-12-31$595.7mus-gaap:LongTermDebtNoncurrent
Shareholders' equityAt period end2021-12-31$5.84bnus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0001099800-22-000005. Last ingested by Listed: Nov 15, 2026, 03:19 ET. Listed shows no prices and gives no investment advice.